AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00139815
Drug: enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enoxaparin 1mg/kg s.c. injection twice daily x 2 to 8 days
Trial: NCT03576053
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine intradermal injection
Trial: NCT04049097
Drug: Arimoclomol
RxNorm normalized name: arimoclomol
DrugBank: Arimoclomol (DB05025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily during breakfast, early afternoon, and at bedtime
Trial: NCT02242344
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00595673
Drug: PB127 for injectable suspension
RxNorm normalized name: PB127
DrugBank: PB127 (DB06208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.175 mg/kg diluted in 150 mL Dextrose in Water 5% in glass bottles to be infused at 250 mL/hour until stead state achieve, 150 mL/hour during rest image acquisition, and 100-150 mL/hr during stress image acquistion. Single IV infusion, not to exceed 60 minutes.
Trial: NCT00271973
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03434691
Drug: remifentanyl
RxNorm normalized name: Remifentanyl
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Only the dose of remifentanyl (initial infusion of 6 µg/kg/h) can be changed to achieve a Goal of sedation: Richmond agitation-sedation scale 0 to -2.
Trial: NCT00002976
Drug: conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02230176
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02230176
Drug: 177Lu-DOTA0-Tyr3-Octreotate
RxNorm normalized name: 177Lu-DOTA-Tyr3-octreotate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00715676
Drug: DP001
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral, once daily
Trial: NCT04117880
Drug: Ataluren
RxNorm normalized name: Ataluren
DrugBank: Ataluren (DB05016)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Oral
Trial: NCT01110954
Drug: PD L 506
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Two different doses will be compared
Trial: NCT03087162
Drug: Dexlansoprazole 60 mg once daily
RxNorm normalized name: dexlansoprazole 60 MG
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily dose dexlansoprazole(Dexlansoprazole(60) OD) in experimental arm and Twice daily dose dexlansoprazole(Dexlansoprazole(60) 1 BID) in active arm
Trial: NCT02373202
Drug: Sarilumab
RxNorm normalized name: Sarilumab
DrugBank: Sarilumab (DB11767)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form:solution
Trial: NCT02373202
Drug: Sulfasalazine
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Tablet Route of administration: Oral
Trial: NCT02373202
Drug: Leflunomide
RxNorm normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Tablet Route of administration: Oral
Trial: NCT02373202
Drug: Bucillamine
RxNorm normalized name: bucillamine
DrugBank: Bucillamine (DB12160)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Tablet Route of administration: Oral
Trial: NCT02373202
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Capsule Route of administration: Oral
Trial: NCT02373202
Drug: Mizoribine
RxNorm normalized name: Mizoribine
DrugBank: Mizoribine (DB12617)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Tablet Route of administration: Oral
Trial: NCT00009776
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00009776
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00246662
Drug: Vosaroxin
RxNorm normalized name: vosaroxin
DrugBank: Vosaroxin (DB11999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients receive vosaroxin Injection
Trial: NCT02927080
Drug: ACE-083
RxNorm normalized name: albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant fusion protein.
Trial: NCT02415881
Drug: Panitumumab IRDye 800
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will receive Panitumumab IRDye 800 prior to their scheduled surgery
Trial: NCT00131716
Drug: sulfadoxine-pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02837094
Drug: C19-A3 GNP
RxNorm normalized name: Kitasamycin A3
DrugBank: Josamycin (DB01321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C19A3 GNP intradermal microinjectable solution of human C19A3 proinsulin peptide coupled to gold.
Trial: NCT01132404
Drug: Leuprorelin
RxNorm normalized name: Leuprorelin
DrugBank: Leuprolide (DB00007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase 2 portion of study: patients randomized to this arm will receive a subcutaneous injection of depot Leuprorelin in the abdomen once per month for up to 6 months
Trial: NCT00344513
Drug: Beta-blockers including Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00858403
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Take tablets of Dasatinib by mouth once a day.
Trial: NCT02177552
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02177552
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02177552
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02177552
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00065949
Drug: magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01132404
Drug: TAK-448
RxNorm normalized name: TAK-448
DrugBank: TAK-448 (DB11975)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1 portion of study:~Patients will be administered a single dose of depot formulation TAK-448 via subcutaneous abdominal injection and a single dose of placebo at a contralateral injection site~Phase 2 portion of the study:~Patients randomized to this arm will be administered depot formulation TAK-448 (up to 2 dose levels) via subcutaneous injection in the abdomen once per month for up to 6 months
Trial: NCT04142658
Drug: Apixaban 5 MG
RxNorm normalized name: apixaban 5 MG
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: For patients that do NOT meet the following criteria~* age ≥ 80 years~* weight ≤ 60 kilograms~* creatinine ≥ 1.5 mg/dL (133 micromol/L)
Trial: NCT04142658
Drug: Apixaban 2.5 MG
RxNorm normalized name: apixaban 2.5 MG
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: For patients that meet at least 2 of the following criteria~* age ≥ 80 years~* weight ≤ 60 kilograms~* creatinine ≥ 1.5 mg/dL (133 micromol/L)
Trial: NCT04142658
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active Control Intervention
Trial: NCT00024258
Drug: arsenic trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01292837
Drug: Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The initial dose is 20 mg/kg/day or 1000 mg/day, divided into two equal dose for the first two weeks, followed by 40 mg/kg/day or 2000 mg/day for two weeks. After reaching 60 mg/kg/day or 3000 mg/day, treatment will continue for 20 weeks.
Trial: NCT01529255
Drug: telbivudine (ROADMAP)
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will receive oral telbivudine 600mg, daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily~Stopping rules:~The participants who achieve HBeAg seroconversion and HBV DNA\<300copies/ml with over 12 months consolidation treatment in EFFORT study will discontinue treatment.~The participants who don't meet the rules above will continue their previous treatment and follow up at the interval of 12 weeks until they finish the 156 weeks therapy or achieve the stopping rules.~Follow up： The participants who stopped treatment will follow up at the interval of 12 weeks for 52 weeks. Of these patients, if they have confirmed virologic relapse during follow-up period, they will be excluded from the trial.
Trial: NCT01529255
Drug: Telbivudine (Standard of Care)
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will receive oral telbivudine 600mg, daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily~Stopping rules:~The participants who achieve HBeAg seroconversion and HBV DNA\<300copies/ml with over 12 months consolidation treatment in EFFORT study will discontinue treatment.~The participants who don't meet the rules above will continue their previous treatment and follow up at the interval of 12 weeks until they finish the 156 weeks therapy or achieve the stopping rules.~Follow up： The participants who stopped treatment will follow up at the interval of 12 weeks for 52 weeks. Of these patients, if they have confirmed virologic relapse during follow-up period, they will be excluded from the trial.
Trial: NCT03684811
Drug: FT-2102
RxNorm normalized name: FT-1101
DrugBank: FT-1101 (DB17553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FT-2102 will be supplied as a 150 mg capsule and will be administered per the protocol defined frequency and dose level.
Trial: NCT03684811
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine will be administered per the site's standard of care.
Trial: NCT03684811
Drug: Gemcitabine and Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine and cisplatin will be administered per the site's standard of care.
Trial: NCT00017498
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00931762
Drug: Panobinostat
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panobinostat oral capsules
Trial: NCT03178864
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 20 mg daily (15 mg daily in participants with a CrCl 30-49 mL/min as per the Cockroft-Gault equation)
Trial: NCT03950674
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT03950674
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion
Trial: NCT03950674
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV infusion
Trial: NCT04037605
Drug: Ketoconazole Pill (also known as nizoral)
RxNorm normalized name: ketoconazole Pill
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole pill is taken 4 times per inpatient visit
Trial: NCT04037605
Drug: Ganirelix
RxNorm normalized name: Ganirelix
DrugBank: Ganirelix (DB06785)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ganirelix subcutaneous injection is administered twice per inpatient visit
Trial: NCT04037605
Drug: Dexamethasone Pill
RxNorm normalized name: dexamethasone Pill
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone pills is taken twice per inpatient visit
Trial: NCT04037605
Drug: Dexamethasone injection
RxNorm normalized name: dexamethasone Injection
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone IV injection is given twice per inpatient visit
Trial: NCT04037605
Drug: Recombinant Human Luteinizing Hormone (also known as luveris)
DrugBank: Lutein (DB00137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant Human Luteinizing Hormone is given as 6 IV infusion pulses per inpatient visit
Trial: NCT04037605
Drug: Gonadorelin (also known as Lutrepulse)
RxNorm normalized name: gonadorelin Injectable Solution [Lutrepulse]
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadorelin IV injection is given twice per inpatient visit
Trial: NCT04037605
Drug: Corticorelin (also known as Acthrel)
RxNorm normalized name: corticorelin
DrugBank: Corticorelin (DB05394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticorelin IV injection is given twice per inpatient visit
Trial: NCT04037605
Drug: Saline Solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline Solution (Placebo) for Dexamethasone IV injection or hydrocortisone IV injection given up to four times per inpatient visit
Trial: NCT03950674
Drug: Dexamethasone 4 mg
RxNorm normalized name: dexamethasone 4 MG
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
Trial: NCT03950674
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT00216060
Drug: Risedronate
RxNorm normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily oral risedronate combined with androgen deprivation
Trial: NCT03949062
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib 560mg per day administered orally on Day 1-21 of each 21-day cycle for 6 cycles
Trial: NCT03949062
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide 25mg per day administered orally on Day 1-10 of each 21-day cycle for 6 cycles
Trial: NCT03949062
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375mg/m2 per day administered intraveneously on Day 1 of each 21-day cycle for 6 cycles
Trial: NCT02174276
Drug: Tenofovir disoproxil fumarate
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TDF 300 mg tablet administered orally once daily
Trial: NCT03680716
Drug: Ropivacaine injection
RxNorm normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saphenous nerve block with 20ml of ropivacaine 0.5% and IPACK block with 30ml of ropivacaine 0.2% (total dose of 160 mg).
Trial: NCT03680716
Drug: Ropivacaine injection
RxNorm normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periarticular infiltration of 80 ml ropivacaine 0.2% (total dose of 160mg).
Trial: NCT03799224
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine 200mg.m-2.d-1 intravenously on days -12 and -11
Trial: NCT00388063
Drug: Atiprimod
RxNorm normalized name: Atiprimod
DrugBank: Atiprimod (DB05513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, 14 days on / 14 days off; 30mg capsules
Trial: NCT00006942
Drug: bryostatin 1
RxNorm normalized name: Bryostatin 1
DrugBank: Bryostatin 1 (DB11752)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00006942
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00003204
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00003204
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00003204
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00972569
Drug: BNP and PDE-V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: low dose BNP 0.025 u/kg/min for 3 hours then 0.005ug/kg/min 45 hours PDE-V 12.5 mg 4 time points
Trial: NCT00972569
Drug: BNP
RxNorm normalized name: BNP
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: low dose BNP at 0.025 u/kg/min if tolerated then at 0.005 ug/kg/min for 45 hours
Trial: NCT03051035
Drug: KO-947
RxNorm normalized name: niacin
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration
Trial: NCT01937689
Drug: Pyrotinib
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib either at 80, 160, 240, 320, 400, 480 mg ....., p.o. once daily.
Trial: NCT02319057
Drug: ORM-12741 MR A
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
DrugBank: ORM-12741 (DB12057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified release formulation of ORM-12741
Trial: NCT02319057
Drug: ORM-12741 IR
RxNorm normalized name: ORM-12741
DrugBank: ORM-12741 (DB12057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release formulation of ORM-12741
Trial: NCT02319057
Drug: ORM-12741 MR B
RxNorm normalized name: ORM-12741
DrugBank: ORM-12741 (DB12057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified release formulation of ORM-12741
Trial: NCT04155840
Drug: Copanlisib
RxNorm normalized name: Copanlisib
DrugBank: Copanlisib (DB12483)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04155840
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00726895
Drug: Quinine Sulfate Capsules 324 mg
RxNorm normalized name: quinine sulfate Oral Capsule
DrugBank: Quinine (DB00468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 324 mg capsule
Trial: NCT02555189
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT02555189
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT00726895
Drug: Quinine Sulfate Capsules 324 mg
RxNorm normalized name: quinine sulfate Oral Capsule
DrugBank: Quinine (DB00468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 x 324 mg capsules
Trial: NCT00061464
Drug: pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00061464
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03254732
Drug: ADI PEG20
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ADI is a recombinant protein cloned from M. hominis and produced in E. coli, and conjugated with PEG of 20,000 mw. Thus ADI-PEG 20 is an arginine degrading enzyme, ADI, coupled to PEG.
Trial: NCT03254732
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab is a PD-1 blocking antibody indicated in the USA for the treatment.
Trial: NCT03398681
Drug: Placebo (Normal saline)
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (0.9% weight/volume (w/v) NaCl)
Trial: NCT02000973
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: General anesthesia combined with thoracic epidural 1% lidocaine
Trial: NCT02000973
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: General anesthesia combined with thoracic epidural 0.25% bupivacaine
Trial: NCT02000973
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: General anesthesia combined with thoracic epidural 0.3% ropivacaine
Trial: NCT03199586
Drug: NP-G2-044
RxNorm normalized name: NP-G2-044
DrugBank: NP-G2-044 (DB14995)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule
Trial: NCT02338414
Drug: Romiplostim
RxNorm normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous Romiplostim (weekly injection) -\> if titrated with maintaining PLT count between 50-200 x 10\^9/L -\> Subcutaneous Romiplostim (biweekly injection)